Neoprobe meets with FDA to review Phase 3 clinical trial results of Lymphoseek drug
 

Neoprobe Corporation, a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced that it recently met with the United States Food and Drug Administration to review the clinical trial results of a Phase 3 investigational new drug, Lymphoseek®.

More...